Les nouveaux médicaments en rhumatologie, inhibiteurs des Janus kinases

The treatment of rheumatoid polyarthritis is based on the early prescribing of an effective long-term treatment such as methotrexate. However, some patients only respond partially, or not at all, to current treatments. New immunosuppressors such as Janus kinase inhibitors are therefore welcome. Tolerance studies are necessary in order to improve the way the potential risks of these medicines are identified and assessed.